

2014
Press release



www.genfit.com

GENFIT IS ADMITTED TO NEW EURONEXT INDEXES INCLUDING SBF 120

Lille (France), Boston (Massachusetts, United States), June 6, 2014 – GENFIT (Euronext: GNFT ; ISIN : FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announces that, following the latest trimestrial review of the Euronext Paris Stock Exchange Indexes on June 5th, 2014, the "Conseil Scientifique des Indices" took the decision to admit GENFIT to the list of companies in the CAC MID 60, CAD MID & SMALL, SBF 120 and CAC ALL TRADABLE indexes.

Euronext announces that these decisions will take effect starting at the trading session of the stock exchange on June 23, 2014.

Jean-François Mouney, Chairman and Chief Executive Officer of GENFIT, declared: *"We are very happy that GENFIT has been rapidly admitted to these selective and well followed indexes, so soon after its listing in compartment B of the Euronext. Included in the admission criteria which most likely played a role in the selection, beyond attaining a certain market capitalization, is the liquidity of the stock and the free float. This will continue to improve the international exposure merited by our Company and its scientific assets."*

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in fields of high medical need due to a lack of suitable treatment and an increasing number of patients worldwide. GENFIT's R&D efforts are focused on contributing to bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH - Nonalcoholic steatohepatitis) or the bowel (such as the inflammatory bowel disease). GENFIT implements mutually beneficial approaches that combine novel treatments and biomarkers; its research programs have resulted in the creation of a rich and diversified pipeline of drug candidates, including GENFIT's lead proprietary compound, GFT505, that is completing a Phase 2b study in NASH.

With facilities in Lille, France, and Boston, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed in compartment B of Euronext's regulated market in Paris (Euronext: GNFT; ISIN: FR0004163111). www.genfit.com

Disclaimer:

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Listing Prospectus upon the admission of Company's shares for trading on the regulated market Euronext of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf-france.org) or on GENFIT's website (www.genfit.com).

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in GENFIT in any country.

Contacts

GENFIT | Jean-François Mouney - CEO & Chairman of the Management Board | Ph. +333 2016 4000

MILESTONES – Relation Presse | Bruno Arabian | Ph. +331 8362 3484 / +336 8788 4726 – barabian@milestones.fr